Hantz Financial Services’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $165K | Buy |
1,312
+683
| +109% | +$85.9K | ﹤0.01% | 648 |
|
|
2025
Q1 | $70K | Sell |
629
-49
| -7% | -$5.45K | ﹤0.01% | 657 |
|
|
2024
Q4 | $93K | Sell |
678
-249
| -27% | -$34.2K | ﹤0.01% | 614 |
|
|
2024
Q3 | $107K | Hold |
927
| – | – | ﹤0.01% | 609 |
|
|
2024
Q2 | $128K | Sell |
927
-15
| -2% | -$2.07K | ﹤0.01% | 593 |
|
|
2024
Q1 | $130K | Sell |
942
-132
| -12% | -$18.2K | ﹤0.01% | 590 |
|
|
2023
Q4 | $142K | Sell |
1,074
-102
| -9% | -$13.5K | ﹤0.01% | 580 |
|
|
2023
Q3 | $132K | Sell |
1,176
-321
| -21% | -$36K | ﹤0.01% | 573 |
|
|
2023
Q2 | $141K | Sell |
1,497
-106,276
| -99% | -$10M | ﹤0.01% | 561 |
|
|
2023
Q1 | $10.9M | Sell |
107,773
-2,003
| -2% | -$203K | 0.3% | 98 |
|
|
2022
Q4 | $13.1M | Sell |
109,776
-46,783
| -30% | -$5.59M | 0.4% | 68 |
|
|
2022
Q3 | $16.6M | Buy |
156,559
+1,399
| +0.9% | +$149K | 0.57% | 36 |
|
|
2022
Q2 | $15.1M | Buy |
155,160
+4,022
| +3% | +$392K | 0.51% | 42 |
|
|
2022
Q1 | $14.2M | Buy |
151,138
+89,462
| +145% | +$8.39M | 0.42% | 68 |
|
|
2021
Q4 | $5.25M | Buy |
61,676
+5,633
| +10% | +$480K | 0.15% | 174 |
|
|
2021
Q3 | $5.38M | Buy |
56,043
+7,526
| +16% | +$722K | 0.18% | 161 |
|
|
2021
Q2 | $4.72M | Buy |
48,517
+1,615
| +3% | +$157K | 0.17% | 159 |
|
|
2021
Q1 | $4.56M | Buy |
46,902
+1,102
| +2% | +$107K | 0.19% | 154 |
|
|
2020
Q4 | $4.39M | Buy |
45,800
+2,930
| +7% | +$281K | 0.2% | 153 |
|
|
2020
Q3 | $4.12M | Buy |
+42,870
| New | +$4.12M | 0.21% | 141 |
|